Rexahn reports positive preliminary results from Phase IIa ED trial
Rexahn Pharmaceuticals, a biopharmaceutical company, has reported preliminary results for its sexual dysfunction drug candidate, Zoraxel, from a Phase IIa clinical study for the treatment of erectile dysfunction.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.